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Abstract
Pyruvate dehydrogenase kinase 4 (PDK4) inhibition by nuclear factor-kB (NF-kB) is related to a shift towards increased
glycolysis during cardiac pathological processes such as cardiac hypertrophy and heart failure. The transcription factors
estrogen-related receptor-a (ERRa) and peroxisome proliferator-activated receptor (PPAR) regulate PDK4 expression
through the potent transcriptional coactivator PPARc coactivator-1a (PGC-1a). NF-kB activation in AC16 cardiac cells inhibit
ERRa and PPARb/d transcriptional activity, resulting in reduced PGC-1a and PDK4 expression, and an enhanced glucose
oxidation rate. However, addition of the NF-kB inhibitor parthenolide to these cells prevents the downregulation of PDK4
expression but not ERRa and PPARb/d DNA binding activity, thus suggesting that additional transcription factors are
regulating PDK4. Interestingly, a recent study has demonstrated that the transcription factor E2F1, which is crucial for cell
cycle control, may regulate PDK4 expression. Given that NF-kB may antagonize the transcriptional activity of E2F1 in cardiac
myocytes, we sought to study whether inflammatory processes driven by NF-kB can downregulate PDK4 expression in
human cardiac AC16 cells through E2F1 inhibition. Protein coimmunoprecipitation indicated that PDK4 downregulation
entailed enhanced physical interaction between the p65 subunit of NF-kB and E2F1. Chromatin immunoprecipitation
analyses demonstrated that p65 translocation into the nucleus prevented the recruitment of E2F1 to the PDK4 promoter
and its subsequent E2F1-dependent gene transcription. Interestingly, the NF-kB inhibitor parthenolide prevented the
inhibition of E2F1, while E2F1 overexpression reduced interleukin expression in stimulated cardiac cells. Based on these
findings, we propose that NF-kB acts as a molecular switch that regulates E2F1-dependent PDK4 gene transcription.
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Introduction
Enlargement of the mammalian heart occurs principally by cell
hypertrophy, since post-natal cardiac myocytes lack the ability to
undergo cell division. This adaptive physiological growth allows
the heart to maintain sufficient cardiac output. Myocardial injury
owing to myocardial infarction or chronic hypertension leads to
pathological hypertrophic growth that may result in heart failure.
Tumor necrosis factor (TNF)-a is a pro-inflammatory cytokine
secreted by the myocardium that has been related to cardiac
hypertrophy and chronic heart failure [1,2]. Inflammatory
cytokines are under the transcriptional control of the ubiquitous
inducible factor named nuclear factor-kB (NF-kB), which has been
linked to various cardiovascular diseases, such as cardiac
hypertrophy and heart failure [3].
The development of pathological cardiac hypertrophy occurs
together with re-activation of the cell cycle machinery of myocytes
[4]. The transcription factor E2F1 is one of the key proteins in the
regulation of the G1/S phase transition, hence it acts as a critical
regulator of cell survival and proliferation [4]. However, E2F1
activity has antagonistic functions, since it may induce cell
proliferation or apoptosis [5]. To form functional transcription
complexes on DNA, E2F1 requires heterodimerization with the
partner differentiation regulated transcription factor (DRTF)
polypeptide DP-1. The transcriptional activity of E2F1 is sterically
inhibited by the retinoblastoma protein (pRB) family of pocket
proteins [6]. When pRB proteins are phosphorylated, the E2F-DP
complex is released, hence E2F-mediated gene transcription
commences.
The heart can adapt to various pathophysiological conditions by
adjusting its relative metabolism of carbohydrates and fatty acids.
Consequently, loss of this metabolic flexibility is associated with
cardiovascular disease. Metabolic changes in cardiac substrate
utilization entail the dysregulation of genes involved in the
transport and catabolism of fatty acids and glucose. The
transcription factors estrogen-related receptor-a (ERRa) and
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peroxisome proliferator-activated receptor (PPAR) regulate the
pyruvate dehydrogenase kinase 4 (PDK4) expression, a key
enzyme in glucose homeostasis modulation [7,8]. In particular,
they regulate PDK4 expression through the potent transcriptional
coactivator PPARc coactivator-1a (PGC-1a) [9,10]. A previous
study performed in our laboratory revealed that NF-kB activation
in cardiac cells inhibited ERRa and PPARb/d DNA binding
activity, which resulted in reduced PGC-1a and PDK4 expression,
and an enhanced glucose oxidation rate [11]. However, addition
of the NF-kB inhibitor parthenolide prevented the downregulation
of PGC-1a and PDK4 expression but not ERRa and PPARb/d
DNA binding activity [11]. Besides, addition of this NF-kB
inhibitor in the absence of TNF-a to human cardiac AC16 cells
[11] or neonatal rat cardiomyocytes [12] induces PDK4 expression
to levels that far exceed those observed at the basal state.
Importantly, this induction is not correlated with an upregulation
in PGC-1a expression or ERRa-PPARb/d transcriptional activity.
These findings reinforce the notion that additional PGC-1a-
independent transcription factors regulate PDK4 to keep cardiac
cell metabolism within a balanced physiological margin in these
cells. Interestingly, recent studies report that E2F1 may regulate
other genes besides those involved in cell-cycle regulation [13,14].
For instance, loss of E2F1 in vivo blunts PDK4 expression, while
exogenous E2F1 overexpression up-regulates PDK4 levels in
mouse myoblasts and IMR90 fibroblasts [14]. Such effects are
driven by the binding of E2F1 to the E2F binding sites located
within the promoter of the gene that encodes for PDK4. On the
other hand, other studies demonstrate that NF-kB may antagonize
the transcriptional activity of E2F1 in cardiac myocytes [15] and
human fibroblasts [16]. Therefore, since NF-kB may antagonize
the transcriptional activity of E2F1, and E2F1 is able to regulate
PDK4, the present study aimed to elucidate whether E2F1 was
involved in the downregulation of PDK4 expression induced by
NF-kB activation in cardiac myocytes.
Results
Inhibition of PDK4 expression by TNF-a coincides with
dysregulation of E2F1 activity in AC16 cells
Addition of TNF-a (100 ng/mL for 24 h) to AC16 cells
inhibited PDK4 expression (,60% reduction, P,0.01,
Figure 1A). Parthenolide not only prevented this, but was also
capable of inducing PDK4 mRNA to levels beyond those observed
in non-stimulated cells. As a first approach, we investigated
whether these changes correlated with dysregulation of the E2F1
signaling pathway. No changes in E2F1 expression were observed
after treatment with TNF-a for 6 h (see Supplementary Figure
S1A) or 24 h (Figure 1A). Cyclin A, whose expression is induced
by E2F1 [17], was not modified in these conditions. Nevertheless,
E2F1 DNA-binding activity displayed some changes when
examined by means of an EMSA (Figure 1B). E2F1 formed
four DNA-binding complexes, namely I to IV, with nuclear
proteins. However, the competitor lane demonstrated that only
complexes I to III were specific for the E2F1 probe, while complex
IV corresponded to a non-specific band. Supershift analyses
demonstrated that complexes I and II contained the E2F1
transcription factor, while pRB was exclusively present in complex
I. Thus, complex I might correspond to a complex containing the
E2F1-DP heterodimer along with pocket proteins such as pRB,
while complexes II and III might represent the free E2F1-DP.
Independently of the presence of TNF-a, parthenolide downreg-
ulated complex I. This NF-kB inhibitor also increased complex II,
particularly in the absence of TNF-a. This suggests that the levels
of pRB bound to E2F1 were downregulated by parthenolide. In
contrast, treatment with TNF-a enhanced the DNA-binding of
complexes I and II (Figure 1B). We next evaluated the protein
levels of E2F1 and pRB. E2F1 remained unaltered in nuclear
protein extracts from AC16 cells treated with TNF-a for 6 h (see
Supplementary Figure S1B) or 24 h (Figure 1C). The addition
of parthenolide did not alter E2F1 protein levels either, although it
significantly enhanced the phosphorylation of pRB at serine 780.
PDK4 expression is regulated by E2F1 in AC16 cells
E2F1 overexpression significantly enhanced E2F1 mRNA levels
(Figure 2A) in human AC16 cells, even in the presence of TNF-a,
compared to control cells transfected with a lacZ-containing
plasmid. Despite the huge increment in E2F1 expression, cyclin A
was not modified. In contrast, PDK4 expression correlated with
E2F1 mRNA levels, which demonstrates that this kinase is
transcriptionally induced by E2F1 in cardiac AC16 cells
(Figure 2A). Furthermore, overexpression of E2F1 partially
counteracted TNF-a-induced PDK4 downregulation in these cells.
Forced E2F1 expression in AC16 cells induced a significant
increase in E2F1 protein accumulation (Figure 2B). Strikingly,
this rise was further enhanced in nuclear protein extracts when
TNF-a was added to the medium. E2F1 levels correlated with
those of total pRB protein, while the ratio phospho-pRBSer780/
pRB was reduced in cells overexpressing E2F1 (Figure 2B).
Overexpression of E2F1 enhanced the DNA-binding activity of
complexes II and III of E2F1 in comparison to the control cells
(Figure 2C), although TNF-a did not alter this activity. The
overall results might explain why PDK4 expression was not
enhanced by TNF-a in cells overexpressing E2F1 when compared
to cells lacking the stimulus, in spite of the increase of E2F1
protein. Subsequently, small interfering RNA (siRNA)-mediated
E2F1 gene silencing was carried out by transfecting AC16 cells
with human E2F1 siRNA. A reduction of up to 40% in E2F1
expression by means of siE2F1 did not reduce PDK4 or cyclin A
expression as compared to control cells transfected with scrambled
siRNA (Figure 3).
TNF-a enhances the physical interaction between the
p65 subunit of NF-kB and E2F1 in human and mouse
cardiac cells
In non-stimulated mammalian cells, NF-kB mostly consists of an
inactive heterodimeric complex comprised of p50 and p65 subunits
sequestered in the cytoplasm by association with the inhibitory IkB
protein. In response to proinflammatory cytokines, IkB is
phosphorylated by the IkB kinase (IKK) complex, which leads to
its degradation by the proteasome. Once IkB is degraded, NF-kB
translocates into the nucleus where it binds to specific promoter sites
on its target genes. However, NF-kBmay also localize to the nucleus
in non-stimulated cells, where it would act as a transcriptional
repressor [15]. Since NF-kB may associate with E2F, we next
investigated whether this mechanism might be involved in the
regulation of PDK4 expression in cardiac cells. Coimmunoprecipi-
tation studies revealed that p65 was constitutively bound to E2F1 in
resting cells, and this binding was increased upon NF-kB activation
with TNF-a (Figure 4A). The opposite behavior was observed after
parthenolide addition. Next, we investigated the effects of knocking
down p65 with a specific siRNA (sip65). Transfection with sip65
downregulated the levels of this protein by up to 30% when
compared to control siRNA [18], and this reduction was sufficient
to prevent the enhanced interaction of p65 with E2F1 induced by
TNF-a (Figure 4B). Then we examined the effect of E2F1 protein
overexpression on its association with the p65 subunit. As shown in
the graph in Figure 4C, overexpression of E2F1 increased the p65-
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E2F1 association (2-fold, P,0.01 vs. LacZ), which was further
enhanced when TNF-a was added to E2F1-transfected cells (4-fold,
P,0.001 vs. LacZ). In contrast, E2F1 gene silencing by means of
siRNA did not influence the binding between E2F1 and p65
proteins (data not shown).
To further confirm the results obtained in vitro, we performed
studies with mice. Transgenic TNF1.6 mice, which present
reduced PDK4 expression in the heart compared with wild-type
mice (see Supplementary Figure S2A), also displayed enhanced
binding of p65 to E2F1 in heart (Figure 4D). Analyses of E2F1
and cyclin A mRNA, as well as E2F1 protein levels, showed no
differences between wild-type and transgenic TNF1.6 mice
(Supplementary Figure S2A and B).
The physical interaction between p65 and E2F1 results in
a diminution of the binding of E2F1 to the PDK4
promoter
Retinoblastoma family proteins (pRB, p107 and p130) inhibit
E2F transcriptional activity by disrupting histone acetyltransferase
binding and the recruitment of histone deacetylases. Since we
observed that parthenolide induced the phosphorylation of pRB at
Ser780, the release of E2F1 and its subsequent acetylation might
account for the enhanced PDK4 expression in AC16 cells.
Therefore, acetylation of E2F1 was examined by means of
coimmunoprecipitation analysis. E2F1 acetylation was not mod-
ified after NF-kB inhibition with parthenolide. In fact, it appeared
to be enhanced by TNF-a (Figure 5A). These results were further
confirmed when E2F1 acetylation was examined in AC16 cells
overexpressing E2F1 (Figure 5B). Thus, we hypothesize that
enhanced acetylation was not involved in PDK4 upregulation, but
it might be a response of the cell to counteract the TNF-a-induced
inhibition of E2F1.
Subsequently, a ChIP assay was employed to determine
whether E2F1 is recruited to the promoter of the PDK4 gene in
cardiac AC16 cells. This analysis showed that the specific anti-
E2F1 antibody, but not the non-immune IgG control, successfully
co-immunoprecipitated E2F1 and significant quantities of PDK4
promoter under basal conditions (Figure 5C). Figure 5C also
reveals that the E2F1 antibody pulled down significantly more of
the PDK4 promoter when the NF-kB inhibitor parthenolide was
added to the medium. In contrast, E2F1-binding to the PDK4
promoter region was largely reduced in the presence of TNF-a. In
support of a role for E2F1 in the transcriptional control of PDK4,
AC16 cells transfected with the pSG5L/E2F1 plasmid displayed
enhanced PDK4 promoter occupancy by E2F1 (Figure 5D). The
negative effect of NF-kB activation by TNF-a on the PDK4
promoter occupancy by E2F1 was further corroborated in cells
overexpressing E2F1 (Figure 5D).
The crosstalk between the p65 subunit of NF-kB and
E2F1 influences TNF-a-induced inflammation and
glucose oxidation in human cardiac cells
Gene expression analyses of IL-6 in cardiac AC16 cells carrying
pSG5L/E2F1 revealed that this transcription factor might inhibit
NF-kB activity in the presence of a proinflammatory stimulus.
Thus, the mRNA for IL-6 was partially inhibited by E2F1
overexpression in the presence of TNF-a when compared to
control LacZ samples (Figure 6A). In contrast, IL-6 mRNA was
upregulated when E2F1 expression was downregulated by siRNA
technology (Figure 6B). The levels of IL-6 secreted into the
medium correlated with the expression of the gene in both cases
(Figure 6C).
Finally, overexpression of the human E2F1 protein reduced the
glucose oxidation rate (,25% reduction, P,0.05, Figure 6D).
Addition of TNF-a to these E2F1-transfected cells increased the
catabolism of glucose (75% vs. 115%), although the increase
observed in control LacZ-transfected cells treated with TNF-a was
not reached (Figure 6D).
Discussion
The progression of heart failure usually entails a local rise in
pro-inflammatory cytokines, such as TNF-a, which mainly act in
an autocrine fashion. In cardiac cells exposed to TNF-a, the
inhibition of PDK4 expression by NF-kB is related to the shift
towards increased glycolysis that is observed during cardiac
pathological processes induced by pro-inflammatory stimuli, such
as cardiac hypertrophy and heart failure [11]. A previous study
performed in our laboratory revealed that NF-kB activation in
cardiac cells inhibited ERRa and PPARb/d DNA binding
activity, which resulted in reduced PDK4 expression and an
enhanced glucose oxidation rate [11]. Addition of the NF-kB
inhibitor parthenolide prevented the downregulation of PDK4
expression but not ERRa and PPARb/d DNA binding activity,
thus suggesting an additional mechanism by which PDK4 is
transcriptionally regulated. Besides ERRa and PPAR, a plethora
of different transcription factors have been proposed to regulate
PDK4 expression, such as FOXO1 (Forkhead box protein O1),
HNF4 (hepatic nuclear factor 4), LXR (liver6receptor) or RXR
(retinoid6receptor) [7,8]. For instance, glucocorticoids stimulate
PDK4 transcription in McA-RH7777 hepatoma cells through two
glucocorticoid receptor binding sites located within the distal
promoter region of the PDK4 gene [19]. Interestingly, PGC-1a
does not appear to be necessary for the acute regulation of PDK4
by glucocorticoids [19]. Nevertheless, we did not found any
change in FOXO1 activity in human cardiac AC16 cells treated
with TNF-a (data not shown), thus ruling out this transcription
factor as a regulator of PDK4 expression in our conditions. For the
first time, we propose a novel mechanism by which the
inflammatory processes driven by NF-kB can downregulate
PDK4 through inhibition of the E2F1 transcription factor in a
PPAR- and ERRa-independent manner. The results demonstrate
that inhibition of PDK4 expression by TNF-a in cardiac AC16
cells coincides with dysregulation in E2F1 activity. In addition, we
show that E2F1 can transcriptionally regulate the PDK4 gene.
E2F1 overexpression did not completely keep AC16 cells away
from the downregulation in PDK4 transcription observed after
TNF-a addition, while silencing E2F1 through siRNA technology
had no effect on PDK4 expression either. In consonance with this,
Figure 1. NF-kB modulation influences E2F1 activity in human cardiac cells. (A) Relative quantification of PDK4, E2F1 and Cyclin A mRNA
levels assessed by RT-PCR in human cardiac AC16 cells incubated with TNF-a (100 ng/mL) for 24 h in the presence or absence of parthenolide (Parth,
10 mmol/L). The graphics represent the quantification of the 18S-normalized mRNA levels, expressed as a percentage of control samples 6STD. (B)
EMSA assay showing E2F1 DNA-binding activity after treatment of AC16 cells with TNF-a in the presence or absence of parthenolide (NE, nuclear
extracts; Ab, antibody). (C) E2F1, phospho-pRBSer780 and total pRB protein levels in nuclear protein extracts isolated from samples as described in
panel A. To show equal loading of protein, the Lamin B signal is also included. The graphics represent the quantification of the normalized protein
levels, expressed as a percentage of control samples 6STD. All autoradiograph data are representative of three separate experiments. *P,0.05,
**P,0.01, ***P,0.001 vs. Control; {P,0.01, { P,0.001 vs. Parth; # P,0.001 vs. TNFa.
doi:10.1371/journal.pone.0019724.g001
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enforced PDK4 expression did not completely suppress glucose
oxidation in human AC16 cells. These data indicate that
additional regulatory mechanisms control PDK4 transcription
and glucose metabolism in cardiac cells, to prevent the deleterious
effects of unrestrained E2F1 activities. Previous studies have
already reported a link between E2F1 and glucose oxidation in
muscle through the transcriptional regulation of PDK4 expression
[14]. This direct interaction between E2F1 and PDK4 might be
aimed at sparing the glycolysis end-product pyruvate for the
synthesis of the lipid and protein intermediates needed for cell
doubling. E2F1 itself stimulates 6-phosphofructo-2-kinase-fruc-
tose-2,6-bisphosphatase, a potent stimulator of glycolysis [20].
The activity and specificity of E2F1 is tightly regulated through
its gene expression and subcellular localization, as well as its
interaction with pRB, phosphorylation or acetylation. These
mechanisms of control do not act in isolation in time and space.
We found that NF-kB activity modulation did not change E2F1
mRNA and protein levels in non-transfected AC16 cells. However,
TNF-a significantly raised the E2F1 protein levels in cells carrying
the pSG5L/E2F1 construct compared to non-stimulated cells.
There is no simple explanation for this anomalous E2F1
accumulation, since it was not observed in control LacZ-
transfected cells. However, increased protein stability owing to
its interaction with p65 cannot be excluded. Regardless of the
reason for the accumulation, the occurrence of higher levels of
pRB concomitantly with a reduction in phospho-pRB levels
suggests that E2F1 activity is tightly controlled in these cells. E2F1
acetylation enhances its transcriptional activity [21] but, unex-
pectedly, we found that E2F1 acetylation was induced by TNF-a,
but not parthenolide. This indicates that enhanced acetylation
might be a response of the cell to counteract the inhibition of E2F1
activity. Alternatively, it might be a consequence of the ability of
IKK to potentiate E2F1 acetylation [22]. Consequently, parthe-
nolide would then completely abrogate such acetylation.
NF-kB, and p65 in particular, is localized inside the nucleus also
under basal conditions, where they may constitutively silence gene
transcription by competing with other transcription factors [15].
The mechanism involved in the E2F1-mediated TNF-a downreg-
ulation of PDK4 expression in AC16 cells entails enhanced
physical interaction between the p65 subunit of NF-kB and E2F1.
Figure 2. E2F1 overexpression induces PDK4 transcription in human cardiac AC16 cells. (A) Relative quantification of E2F1, PDK4 and
cyclin A mRNA levels assessed by RT-PCR in human cardiac AC16 cells treated with or without TNF-a (100 ng/ml, 24 h) and transfected with LacZ- or
E2F1-carrying plasmids, as described in Figure 1A. (B) E2F1, phospho-pRBSer780 and total pRB protein levels in nuclear protein extracts. To show equal
loading of protein, the Lamin B signal from the same blot is included. The graphics represent the quantification of the normalized protein levels,
expressed as a percentage of control samples6STD. (C) EMSA assay showing E2F1 DNA-binding activity after treatment of AC16 cells as described in
panel A (NE, nuclear extracts; Ab, antibody). All autoradiograph data are representative of three separate experiments. *P,0.05, **P,0.01,
***P,0.001 vs. LacZ; {P,0.05 vs. E2F1; $P,0.01 vs. LacZ+TNF-a.
doi:10.1371/journal.pone.0019724.g002
Figure 3. E2F1 gene silencing does not enhance the TNF-a-mediated PDK4 inhibition. Relative quantification of E2F1, PDK4 and cyclin A
mRNA levels assessed by RT-PCR in human cardiac AC16 cells treated with or without TNF-a and transfected with scrambled siRNA (siControl) or
siE2F1. The graphics represent the quantification of the 18S-normalized mRNA levels, expressed as a percentage of control samples 6STD. All
autoradiograph data are representative of three separate experiments. *P,0.05, **P,0.01 vs. siRNA Control; &P,0.01 vs. siE2F1.
doi:10.1371/journal.pone.0019724.g003
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Importantly, this association was also observed in vivo in heart of
TNF1.6 mice. Chromatin immunoprecipitation analyses demon-
strated that NF-kB translocation to the nucleus prevented the
recruitment of E2F1 to the PDK4 promoter and its subsequent
E2F1-mediated gene transcription. This view is supported by two
observations: E2F1 binding to the PDK4 promoter was reduced in
TNF-a-treated cells; and parthenolide prevented this reduction.
Importantly, parthenolide not only prevented the binding between
p65-E2F1 by reducing translocation of the former into the
nucleus, but would also activate E2F1 through enhanced pRB
phosphorylation, thus releasing the active E2F-DP complex. This
latter mechanism might account for the upregulation of PDK4
expression induced by parthenolide in the absence of a
proinflammatory stimulus. The association between p65 and
E2F1 has already been established in human fibroblasts, in which
this physical interaction disrupts the E2F-responsive gene
expression [16]. Likewise, E2F1 has been reported to disrupt
antiapoptotic NF-kB signaling through downregulation of the NF-
kB activator TNF receptor-associated factor 2 [23,24], by
competing with p50 for RelA/p65 binding in murine fibroblasts
[24] or inhibiting the phosphorylation of IkB [25]. In human
AC16 cardiac cells, IL-6 expression and secretion was further
induced after E2F1 gene silencing, but downregulated by E2F1
overexpression. This indicates that E2F1 in these cells acts as a
repressor of NF-kB activity. Although we only demonstrate the
physical association of E2F1 with p65, it is feasible that other NF-
kB subunits interact with this transcription factor, since other
studies have revealed that exogenous E2F1 can associate with both
Figure 4. p65 subunit of NF-kB and E2F1 are physically associated in cardiac cells. Protein extracts were immunoprecipitated using an
anti-p65 antibody and then subjected to SDS-PAGE and immunoblotted with an anti-E2F1 antibody. The graphics represent the quantification of the
immunoprecipitated protein normalized to its corresponding control samples, expressed as a percentage 6STD. The blot data are representative of
three separate experiments. (A) AC16 cells treated with TNF-a (100 ng/ml, 24 h) in the presence or absence of parthenolide (Parth, 10 mmol/L). (B)
AC16 cells treated with or without TNF-a and transfected with specific siRNA to p65. (C) AC16 cells treated with or without TNF-a and transfected
with LacZ- or E2F1-carrying plasmids. (D) TNF1.6 or control wild type (WT) mice. (A) and (B) *P,0.05, **P,0.01 vs. Control; {P,0.01 vs. TNFa. (C)
*P,0.05, **P,0.01, ***P,0.001 vs. LacZ; {P,0.001 vs. E2F1. (D) *P,0.05 vs. WT.
doi:10.1371/journal.pone.0019724.g004
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RelA and p50 upon LPS stimulation [26]. The occurrence of
additional mechanisms involving other E2Fs on the effects induced
by NF-kB activation cannot be excluded either. Thus, it has been
reported that IKKs may directly phosphorylate E2F4 in human
fibroblasts. This results in nuclear accumulation of E2F4 and
subsequent replacement of the activator E2F1 at the E2F-binding
element in responsive gene promoters [16].
In the myocardium, glucose is catabolized predominantly by the
aerobic glycolytic pathway [27]. PDK4 is the kinase responsible
for the phosphorylation-induced inactivation of the pyruvate
dehydrogenase complex, which catalyzes the rate-limiting step of
aerobic glucose oxidation. Under certain circumstances, such as
cardiac hypertrophy or heart failure, reliance on the glycolytic
pathways is increased due to the downregulation of PDK4 activity.
Based on our findings, we envision a model for the regulation of
PDK4 expression and cardiac cell metabolism by NF-kB and
E2F1, in which NF-kB serves as a molecular switch that regulates
E2F1-dependent PDK4 gene transcription. As inappropriate
PDK4 activity would have catastrophic consequences in high-
metabolic-rate organs, the basal repression of E2F1-dependent
PDK4 expression by NF-kB might be crucial for normal cardiac
function. Since E2F1 plays an important role in cardiac myocyte
growth and is also involved in metabolism regulation through
PDK4 modulation, targeting this transcription factor could provide
us with an effective therapy for treating detrimental left ventricular
hypertrophy leading to heart failure. This is of particular
relevance, since cardiac hypertrophy and chronic heart failure
have both been related to inflammatory processes in the
Figure 5. TNF-a inhibits PDK4 promoter occupancy by E2F1. (A) and (B), protein extracts of AC16 cells treated with TNF-a (100 ng/mL, 24 h) in
the presence or absence of 10 mmol/L parthenolide (A) or transfected with LacZ- or E2F1-carrying plasmids (B) were subjected to
immunoprecipitation using an anti-E2F1 antibody. They were then subjected to SDS-PAGE and immunoblotted with an anti-acetyl-lysine antibody.
The graphics represent the quantification of the immunoprecipitated protein normalized to its corresponding control samples, expressed as a
percentage 6STD. The blot data are representative of three separate experiments. (C) and (D), chromatin immunoprecipitation from AC16 cells
incubated with TNF-a in the presence or absence of parthenolide (C); or AC16 cells treated with TNF-a and transfected with LacZ- or E2F1-carrying
plasmids (D). The graphics represent the E2F1-site fold enrichment at the PDK4 promoter, expressed as a percentage of control (C) or LacZ (D)
samples 6STD. (A) and (C) *P,0.05, **P,0.01 vs. Control; {P,0.05, {P,0.01 vs. Parth; # P,0.05 vs. TNFa. (B) and (D) *P,0.05 vs. LacZ; {P,0.05 vs.
LacZ+TNF-a; &P,0.05 vs. E2F1.
doi:10.1371/journal.pone.0019724.g005
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myocardium and we have also demonstrated that triggering E2F1
in human cardiac cells partially abrogates cytokine secretion.
Methods
Reagents
D-[U-14C]-glucose, [a-32P]-dATP and [c-32P]-ATP were pur-
chased from PerkinElmer (Waltham, MA, USA). All chemicals,
except when indicated, were purchased from Sigma-Aldrich
Quı´mica (Madrid, Spain). The antibodies utilized throughout
the study were purchased from Cell Signaling Technology
(Danvers, MA, USA), except Oct-1 and p65, which were from
Santa Cruz Biotechnology (Inc., Heidelberg, Germany), and
Lamin B (from Sigma-Aldrich Quı´mica).
Cell culture and transient transfection studies
Human cardiac AC16 cells were maintained and grown as
previously described [28]. In brief, non-differentiated AC16 cells
were maintained in medium composed of Dulbecco’s modified
Eagle’s medium (DMEM):F12 (Invitrogen, Barcelona, Spain)
supplemented with 12.5% foetal bovine serum (FBS), 1%
penicillin-streptomycin and 1% Fungizone (Invitrogen), and
grown at 37uC in a humid atmosphere of 5% CO2/95% air until
they reached 70–80% confluence. For in vitro overexpression
Figure 6. The crosstalk between the p65 subunit of NF-kB and E2F1 influences inflammation and glucose oxidation. (A) and (B),
Relative quantification of IL-6 mRNA levels assessed by RT-PCR in human cardiac AC16 cells transfected with LacZ- or E2F1-carrying plasmids (A) or
with control siRNA (siCtrl) and siE2F1 (B) and treated with or without TNF-a (100 ng/ml) for 8 h (A) or 24 h (B). Graphics represent the quantification
of the 18S-normalized mRNA levels, expressed as a percentage of control samples 6STD. The blot data are representative of three separate
experiments. (C) Levels of IL-6 (ng/mL) in the same samples as described in Panels A and B. (D) [U-14C]-glucose oxidation rates in AC16 cells
overexpressing the human LacZ-control or the E2F1 genes incubated with TNF-a. (A), (C), and (D) *P,0.05, **P,0.01, ***P,0.001 vs. LacZ; {P,0.01
vs. E2F1; &P,0.01 vs. LacZ+TNF-a. (B) *P,0.05, **P,0.01, ***P,0.001 vs. siCtrl; {P,0.001 vs. siCtrl+TNF-a; & P,0.001 vs. siE2F1.
doi:10.1371/journal.pone.0019724.g006
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studies, cells were transfected with Lipofectamine 2000 in OPTI-
MEM reduced serum medium, following the manufacturer’s
recommendations (Invitrogen). For in vitro overexpression studies,
the constructs used were pSG5L/E2F1 construct (human gene,
Addgene plasmid 10736, Cambridge, MA, USA) [6] and the
corresponding LacZ-carrying plasmid as a control. Transfection
time and the DNA to Lipofectamine ratio for overexpression
studies were set after optimization with the corresponding LacZ-
carrying plasmid and using a b-galactosidase reporter gene
staining kit (Sigma-Aldrich Quı´mica). Small interfering RNA
(siRNA)-mediated E2F1 gene silencing was carried out by
transfecting AC16 cells with human E2F1 siRNA (Santa Cruz
Biotechnology), using scrambled siRNA as a transfection control.
Fluorescein-labeled siRNA was used to optimize siRNA transfec-
tions by means of fluorescence microscopy.
Preparation of cardiac samples from TNF-a transgenic
mice
We used transgenic male TNF1.6 mice (8 to 12 –weeks old) with
cardiac-specific overexpression of TNF-a, which has been
established as a suitable model of cytokine-induced cardiomyop-
athy [29]. Mice were anaesthetized with 5% isoflurane and, after
monitoring the adequacy of anaesthesia by testing of rear foot
reflexes, they were euthanized by cervical dislocation. After this,
the heart was excised, rinsed in ice-cold PBS and snap-frozen in
liquid nitrogen [30]. The study was approved by the Thomas
Jefferson University’s Institutional Animal Care and Use Com-
mittee and conformed to the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (NIH
Publication No. 85-23, revised 1996).
RNA preparation and analysis
Relative levels of specific mRNAs were assessed by the reverse
transcription-polymerase chain reaction (RT-PCR) [31]. Briefly,
total RNA was isolated using the Ultraspec reagent (Biotecx,
Houston, TX). RNA samples were cleaned (NucleoSpin RNA II;
Macherey-Nagel, Du¨ren, Germany) and checked for integrity by
agarose gel electrophoresis. The total RNA isolated by this method
was undegraded and free of protein and DNA contamination.
Reverse transcription was performed from 0.5 mg total RNA using
Oligo(dT)23 and M-MLV Reverse Transcriptase (Invitrogen).
Preliminary experiments were carried out with various amounts of
cDNA to determine nonsaturating conditions of PCR amplification
for all the genes studied. Therefore, under these conditions, relative
quantification of mRNA was assessed by the RT-PCR method
described in this study [32]. Radioactive bands were quantified by
video-densitometric scanning. The results for the expression of
specific mRNAs are always presented relative to the expression of
the control gene. The sequences of the forward and reverse primers
used for amplification are shown in Supplementary Table S1.
Electrophoretic mobility shift assay (EMSA) and
immunoblot analysis
Nuclear extracts (NE) from AC16 cells were isolated as
previously reported [31]. To obtain total proteins, AC16 cardiac
cells or frozen tissue slides were homogenized in cold lysis buffer
(5 mM Tris-HCl, pH 7.4, 1 mM EDTA, 0.1 mM phenylmethyl-
sulfonyl fluoride, 1 mM sodium orthovanadate, and 5.4 mg/mL
aprotinin). The homogenate was centrifuged at 10,000g for
30 min at 4uC. Protein concentration was determined using the
Bradford method [33].
Electrophoretic mobility shift assay (EMSA) were performed
using double-stranded oligonucleotides for the consensus binding
site of E2F1 (Santa Cruz Biotechnology). Oligonucleotides were
labeled by incubating the following reaction at 37uC for 2 hours:
2 mL oligonucleotide (1.75 pmol/mL), 2 mL of 56 kinase buffer,
1 mL of T4 polynucleotide kinase (10 U/mL), and 2.5 mL [c-32P]
ATP (3,000 Ci/mmol at 10 mCi/mL). The reaction was stopped
by adding 90 mL of TE buffer (10 mM Tris-HCl, pH 7.4, and
1 mM EDTA). To separate the labeled probe from the unbound
ATP, the reaction mixture was eluted in a Nick column
(Pharmacia, Sant Cugat, Spain) according to the manufacturer’s
instructions. Five micrograms of crude nuclear protein were
incubated for 10 min on ice in binding buffer (10 mM Tris-HCl,
pH 8.0, 25 mM KCl, 0.5 mM dithiothreitol, 0.1 mM EDTA,
pH 8.0, 5% glycerol, 5 mg/mL BSA, and 50 mg/ml poly[dI-dC])
in a final volume of 15 mL. Then, specific competitor oligonu-
cleotide or antibody for supershift assays were added and
incubated for 15 minutes on ice. Subsequently, the labeled probe
(100,000 cpm) was added and the reaction was incubated for an
additional 15 minutes on ice. Finally, protein-DNA complexes
were resolved by electrophoresis at 4uC on 5% polyacrylamide
gels in 0.56 Tris-borate-EDTA buffer and subjected to
autoradiography.
Protein extracts were separated by SDS-PAGE on 10%
separation gels and transferred to Immobilon polyvinylidene
diflouride membranes (Millipore, Bedford, MA), as previously
described [31]. Detection was achieved using the EZ-ECL
chemiluminescence detection kit (Biological Industries, Beit
Haemek, Israel). The size of detected proteins was estimated
using protein molecular mass standards (Invitrogen).
Coimmunoprecipitation and Chromatin
immunoprecipitation (ChIP) studies
For coimmunoprecipitation, cell nuclear extracts (25 mg) were
brought to a final volume of 250 ml with buffer containing
10 mM PBS, 50 mM KCl, 0.05 mM EDTA, 2.5 mM MgCl2,
8.5% glycerol, 1 mM dithiothreitol, 0.1% Triton X-100, BSA
2% and 1 mg/ml nonfat milk for 6 hours at 4uC and incubated
with 4 mg of anti-p65. Immunocomplex was captured by
incubating the samples with 50 ml protein A–agarose suspension
(Santa Cruz Biotechnology) overnight at 4uC on a rocker
platform. Agarose beads were collected by centrifugation and
washed three times with PBS containing protease inhibitors.
After microcentrifugation, the pellet was washed with 25 ml
of SDS-PAGE sample buffer and boiled for 5 min at 100uC.
The resultant supernatant was subjected to electrophoresis on
10% SDS-PAGE and immunoblotted with the corresponding
antibodies.
Chromatin immunoprecipitation (ChIP) was performed with
the ChIP Kit (Abcam, Cambridge, UK), using an E2F1-specific
antibody. Input DNA, mock samples and E2F1-immunoprecipi-
tated DNA were subjected to real-time PCR analysis with
sequence-specific primers surrounding the E2F1 sites in the
PDK4 promoter, along with primers capable of amplifying the
genomic sequence lacking E2F binding sites (negative control, data
not shown) [11]. Mock immunoprecipitations correspond to
control reactions lacking antibodies. Results are reported as
E2F1 site fold enrichment, expressed as a percentage of control
samples 6STD, after normalization to the sample specific
background and to the total input DNA.
Glucose oxidation
AC16 cells were grown in 6-well plates as described above.
Following transfection, 1 mL of reaction mixture (25 mmol/L
NaHCO3, pH 7.4, 1.2 mmol/L MgSO4, 0.5 mmol/L CaCl2,
10 mmol/L HEPES, 1 mCi/mL D-[U-14C]-glucose) containing
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1 mmol/L insulin was added to each well. After incubation for
60 minutes at 37uC in a water bath with gentle shaking, reactions
were stopped by the injection of 100 mL 60% (w:v) perchloric acid,
and the plates were kept at 4uC overnight to trap the CO2
produced. The release of 14CO2 from glucose was measured by
scintillation counting of the filter paper for 1 minute in a b-
counter. Wells containing no cells were used as blanks. Glucose
oxidation rates were calculated as nanomoles of added glucose?g21
total protein total?hour21, and then expressed as a percentage with
respect to control cells.
Statistical Analysis
Results are expressed as the mean 6SD of at least three
separate experiments. Significant differences were established by
either the Student’s t test or one-way ANOVA, according to the
number of groups compared, using the computer program
GraphPad Prism (GraphPad Software Inc V4.03, San Diego,
CA, USA). When significant variations were found by one-way
ANOVA, the Tukey-Kramer multiple comparisons post-test was
performed.
Supporting Information
Figure S1 E2F1 levels are not modified after NF-kB
modulation. (A) Relative quantification of E2F1 mRNA levels
assessed by RT-PCR in human cardiac AC16 cells incubated with
TNF-a (100 ng/mL) for 6 h in the presence or absence of
parthenolide (Parth, 10 mmol/L). The graphics represent the
quantification of the 18S-normalized mRNA levels, expressed as a
percentage of control samples 6STD. (B) E2F1 protein levels in
nuclear protein extracts isolated from samples as described in
panel A. To show equal loading of protein, the Lamin B signal is
also included. All autoradiograph data are representative of three
separate experiments.
(TIF)
Figure S2 NF-kB activation in transgenic TNF1.6 mice
does not modulate E2F1 levels. (A) Relative quantification of
PDK4, E2F1 and Cyclin A mRNA levels assessed by RT-PCR in left
ventricle tissue of transgenic TNF1.6 and control wild-type (WT)
mice. Graphs represent the quantification of the Aprt-normalized
mRNA levels, expressed as a percentage of control samples
6STD. (B) E2F1 protein levels in nuclear protein extracts isolated
from samples as described in panel A. To show equal loading of
protein, the Lamin B signal is also included. The graphics
represent the quantification of the normalized protein levels,
expressed as a percentage of control samples 6STD. All
autoradiograph data are representative of three separate experi-
ments. *P,0.05, **P,0.01, and ***P,0.001 vs. WT
(TIF)
Table S1 Primers used for the RT-PCR reactions.
(DOC)
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